Brought to you by 
Protiva Biotherapeutics completes private financing round
29 May 2003
Executive Summary
Protiva Biotherapeutics (gene delivery technology) has received $5.6mm with the closing of the first of a two tranche $9.1mm ($Cdn14.5mm) private placement. The second tranche will be completed pending the achievement of milestones. Lead investor MDS Capital was joined by Working Opportunity Fund (managed by GrowthWorks Capital), GrowthWorks Access Fund, Business Development Bank of Canada, Kinetic Capital, BioFuture Fund, and Qwest Emerging Biotech.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Protiva Biotherapeutics completes private financing round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice